ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.924,19
-1,12%
S&P 500
5.035,69
-1,57%
US Dollar vs BRL
5,1953
0,00%
Bitcoin
60.214,65
-0,63%
Brent Oil
85,595
-0,35%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) Notícias

AGEN

Agenus (AGEN)

Agenus Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGEN
DataHoraFonteTítuloCódigoCompanhia
24/04/202411:00Business WireBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingNASDAQ:AGENAgenus Inc
23/04/202408:30Business WireAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
12/04/202408:30Business WireAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerNASDAQ:AGENAgenus Inc
05/04/202417:30Business WireAgenus Announces Reverse Stock Split of Common StockNASDAQ:AGENAgenus Inc
14/03/202408:30Business WireAgenus Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:AGENAgenus Inc
06/03/202409:30Business WireAgenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024NASDAQ:AGENAgenus Inc
05/03/202418:30Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
29/02/202418:50Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AGENAgenus Inc
29/02/202409:30Business WireAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportNASDAQ:AGENAgenus Inc
26/02/202418:24Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGENAgenus Inc
26/02/202409:30Business WireAgenus to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:AGENAgenus Inc
15/02/202410:02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGENAgenus Inc
15/02/202410:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
15/02/202409:02PR Newswire (US)Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular DesignNASDAQ:AGENAgenus Inc
14/02/202410:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
12/02/202409:00Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
31/01/202409:30Business WireAgenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:AGENAgenus Inc
22/01/202411:59Business WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
04/01/202409:30Business WireAgenus to Participate in B. Riley Healthcare ConferenceNASDAQ:AGENAgenus Inc
04/01/202408:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
20/12/202309:30Business WireBotensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024NASDAQ:AGENAgenus Inc
11/12/202309:30Business WireAgenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific ProgramNASDAQ:AGENAgenus Inc
09/11/202318:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
07/11/202308:30Business WireAgenus Reports Third Quarter 2023 ResultsNASDAQ:AGENAgenus Inc
26/10/202310:05Business WireAgenus to Provide Third Quarter 2023 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
22/10/202313:00Business WireAgenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and SarcomaNASDAQ:AGENAgenus Inc
21/10/202305:15Business WireESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma SubtypesNASDAQ:AGENAgenus Inc
10/10/202308:30Business WireAgenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal CancerNASDAQ:AGENAgenus Inc
05/10/202308:30Business WireAgenus To Host BOT/BAL Program Update at ESMO 2023NASDAQ:AGENAgenus Inc
28/08/202308:30Business WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGEN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados